This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:diseases:hiv_and_aids [02.17.2019] – [AIDS patients on the Marshall Protocol] sallieq | home:diseases:hiv_and_aids [02.17.2019] – [CD38] sallieq | ||
---|---|---|---|
Line 10: | Line 10: | ||
- | ===== CD38 ===== | ||
- | CD38 plays a role in effective containment of mycobacteria within granulomata and polarization of Th1 immune responses against Mycobacterium avium. (({{pubmed> | ||
- | ... | + | ===== Vitamin D metabolism ===== |
- | Absence of CD38 rendered mice more susceptible to mycobacterial infection. This susceptibility seems to be due to ineffective Th1 differentiation and polarization, | + | |
- | ... | + | |
+ | < | ||
- | CD38 Controls | + | HIV uses the VDR to recognize its own LTR promoter region |
- | Using a murine Listeria monocytogenes infection model, we found that CD38 knockout (KO) mice were highly susceptible | + | |
- | CD38 was expressed on neutrophils and inflammatory monocytes, and especially inflammatory monocytes further upregulated CD38 during infection. Absence of CD38 caused alterations of the migration pattern of both cell types to sites of infection. | + | {{section>: |
- | ... | + | |
- | In vitro, macrophages of CD38 KO mice were less efficient in uptake of listeria but still able to kill the bacteria. Dendritic cells also displayed enhanced CD38 expression following infection. However, absence of CD38 did not impair the capacity of mice to prime CD8+ T cells against L. monocytogenes, | + | There is no evidence that supplemental vitamin D helps HIV or AIDS patients. |
- | CD38 and immune | + | < |
+ | |||
+ | Of note, we observed that patients with low vitamin D levels displayed a reduced CD4/CD8 ratio (P ¼ 0.03, Table 1), which is usually a sign of increased immune activation in HIV-infected patients receiving effective ART [16]. We also analyzed | ||
+ | |||
+ | We thus monitored CD4/CD8 ratio, as well as cellular activation (i.e. CD38 expression) | ||
+ | |||
+ | |||
+ | |||
+ | ===== HIV allows opportunistic infections to proliferate ===== | ||
+ | |||
+ | < | ||
+ | |||
+ | Pathogens are able spread effectively in an immunocompromised environment. This means it's possible that AIDS patients pick up substantial pathogen loads. It is further possible that it is these Th1 pathogens, which kill patients. Viral co-infections (including Epstein-Barr virus, Human Herpes Virus 6, etc.) are found in all the diseases the Marshall Protocol treats, but the viruses are not believed to bethe proximate cause of disease. | ||
+ | |||
+ | |||
+ | |||
+ | ===== AIDS patients on the Marshall Protocol ===== | ||
+ | |||
+ | |||
+ | The ARF has no clinical experience with AIDS patients yet. However, we do believe it due time that ' | ||
+ | |||
+ | We would argue that it would make sense for an AIDS patient to strengthen his or her immune response and that the only way to do this is to kill the Th1 pathogens which dysregulate it. | ||
+ | |||
+ | A therapeutic probe will confirm the potential efficacy of this treatment. | ||
+ | |||
+ | |||
+ | ===== More research into CD38 and immune function ===== | ||
+ | |||
In mice, CD38 was shown to be required for immunity against S. pneumoniae, as its absence rendered mice more susceptible to infection by this pathogen. This increased susceptibility was associated with a diminished neutrophil chemotaxis in response to peptides of bacterial origin. In humans, CD38 was proposed to have a protective role in HIV infection. However, the mechanisms by which this protection is achieved are, at this point, unclear. As CD38 appears to be important in viral infections and is able to modulate immune responses, namely at the level of Th1 cytokine secretion, it is conceivable that it could also play a role in immunity against intracellular pathogens, such as mycobacteria. | In mice, CD38 was shown to be required for immunity against S. pneumoniae, as its absence rendered mice more susceptible to infection by this pathogen. This increased susceptibility was associated with a diminished neutrophil chemotaxis in response to peptides of bacterial origin. In humans, CD38 was proposed to have a protective role in HIV infection. However, the mechanisms by which this protection is achieved are, at this point, unclear. As CD38 appears to be important in viral infections and is able to modulate immune responses, namely at the level of Th1 cytokine secretion, it is conceivable that it could also play a role in immunity against intracellular pathogens, such as mycobacteria. | ||
Line 67: | Line 91: | ||
- | |||
- | |||
- | ===== Vitamin D metabolism ===== | ||
- | |||
- | < | ||
- | |||
- | HIV uses the VDR to recognize its own LTR promoter region in order to transcribe its own genome, thus taking over the VDR.(({{pubmed> | ||
- | |||
- | {{section>: | ||
- | |||
- | There is no evidence that supplemental vitamin D helps HIV or AIDS patients. | ||
- | |||
- | < | ||
- | |||
- | Of note, we observed that patients with low vitamin D levels displayed a reduced CD4/CD8 ratio (P ¼ 0.03, Table 1), which is usually a sign of increased immune activation in HIV-infected patients receiving effective ART [16]. We also analyzed CD38 expression on the surface of memory CD8+ T cells as a robust marker of immune activation. Although there was substantial interindividual variability, | ||
- | |||
- | We thus monitored CD4/CD8 ratio, as well as cellular activation (i.e. CD38 expression) and cell cycling (i.e. Ki67 expression) of memory CD8+ T cells in vitamin D supplemented individuals. These patients presented a higher CD4/CD8 ratio post-compared with pre-supplementation (Fig. 1b). Moreover, vitamin D increase upon supplementation was associated with a reduction in cellular immune activation levels (Fig. 1c). We also found that serum levels of vitamin D and the expression of the cellular immune activation markers were inversely correlated in this longitudinal setting (Fig. 1d). Vitamin D status appears therefore to impact on cellular immune activation levels.</ | ||
- | |||
- | |||
- | |||
- | ===== HIV allows opportunistic infections to proliferate ===== | ||
- | |||
- | < | ||
- | |||
- | Pathogens are able spread effectively in an immunocompromised environment. This means it's possible that AIDS patients pick up substantial pathogen loads. It is further possible that it is these Th1 pathogens, which kill patients. Viral co-infections (including Epstein-Barr virus, Human Herpes Virus 6, etc.) are found in all the diseases the Marshall Protocol treats, but the viruses are not believed to bethe proximate cause of disease. | ||
- | |||
- | |||
- | |||
- | ===== AIDS patients on the Marshall Protocol ===== | ||
- | |||
- | |||
- | The ARF has no clinical experience with AIDS patients yet. However, we do believe it due time that ' | ||
- | |||
- | We would argue that it would make sense for an AIDS patient to strengthen his or her immune response and that the only way to do this is to kill the Th1 pathogens which dysregulate it. | ||
- | |||
- | A therapeutic probe will confirm the potential efficacy of this treatment. | ||